NCT06572475
USPIO Enhanced MR Imaging in CNS Tumours (UMIC)
Recruiting · Not Applicable · Northern Care Alliance NHS Foundation Trust · registry updated 2024-08-27
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The immune response or inflammation is known to be a key driver of progression and growth in many solid tumours. Inflammatory cells called macrophages are present in high numbers in many brain tumours and these tumour associated macrophages or TAM are thought to have prognosis and treatment implications in these tumours. A key question, however, is how this inflammation or TAM abundance can be detected, measured and monitored in the clinic. A clinically applicable imaging test that can directly and accurately measure tumour macrophage content would be of considerable value and one technique that may provide this is USPIO enhanced magnetic resonance imaging (MRI). Following intravenous injection, USPIO or ultrasmall superparamagnetic iron oxide nanoparticles, circulate in the bloodstream before being taken up by inflammatory cells/macrophages in tumour tissue, wherein they can be detected by MRI. This pilot study is to evaluate if a commercially available USPIO preparation called ferumoxytol (Feraheme ©) can accurately quantify macrophage abundance in brain tumours, with an exploratory focus on vestibular schwannoma (VS) and suspected transforming low-grade glioma (LGG)....
Inclusion
- Be at least 16 years old
- Have a CNS tumour suspected to be one of the defined histological types (vestibular scwhannoma or low grade glioma)
- Be able to lie still for up to 1 hour comfortably
- Opinion of the treating clinician is that the patient will be able to successfully complete the research imaging protocol.
Exclusion
- Life expectancy less than 1 year
- Previous CNS radiotherapy/ stereotactic radiosurgery (SRS)
- Females who are pregnant/ breastfeeding
- Patients with an eGFR \< 30ml/min
- Patients with known and documented history of iron overload/haemosiderosis/ haemochromatosis
- Patients with immune or inflammatory conditions e.g. systemic lupus erythematous, rheumatoid arthritis